As Biotechnology companies, Verona Pharma plc (NASDAQ:VRNA) and Benitec Biopharma Limited (NASDAQ:BNTC) are our subject to contrast. And more specifically their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc	N/A	0.00	N/A	-2.34	0.00
Benitec Biopharma Limited	N/A	0.00	N/A	-0.82	0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Verona Pharma plc and Benitec Biopharma Limited.

Profitability

Table 2 has Verona Pharma plc and Benitec Biopharma Limited’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc	0.00%	0%	0%
Benitec Biopharma Limited	0.00%	0%	0%

Institutional & Insider Ownership

Verona Pharma plc and Benitec Biopharma Limited has shares held by institutional investors as follows: 65.7% and 4.11%.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Verona Pharma plc	0.35%	-0.1%	-47.23%	-56.64%	-54.61%	-39.79%
Benitec Biopharma Limited	32.73%	44.42%	-9.25%	-22.06%	-33.96%	46%

For the past year Verona Pharma plc has -39.79% weaker performance while Benitec Biopharma Limited has 46% stronger performance.

Summary

On 2 of the 2 factors Benitec Biopharma Limited beats Verona Pharma plc.

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.